Department of Surgery, School of Medicine, Keio University, Tokyo, Japan.
Department of Surgery, Ito Hospital, Tokyo, Japan.
Ann Surg Oncol. 2019 Oct;26(11):3711-3717. doi: 10.1245/s10434-019-07476-8. Epub 2019 Jun 11.
Cervical esophageal cancer (CEC) patients whose larynx function cannot be preserved often undergo chemoradiotherapy, whereas those with residual or recurrent lesions undergo a pharyngo-laryngo-esophagectomy (PLE); however, some need to undergo a pharyngolaryngectomy with total esophagectomy (PLTE) for synchronous or metachronous esophageal cancer. We retrospectively evaluated the relationship between preoperative irradiation (or the extent of esophageal resection) and postoperative endocrine complications in CEC, including hypothyroidism and hypoparathyroidism.
The cancers of 35 (5.4%) of 678 esophageal cancer patients with esophagectomy treated in 2000-2017 were CECs. We also analyzed the 17 cases of CEC patients who underwent PLE with thyroid lobectomy-11 with irradiation before PLE and 6 without irradiation. Seven patients underwent a PLTE.
Hypothyroidism and hypoparathyroidism occurred in 14 and 12 patients, respectively. The hypothyroidism rate was significantly higher in patients with irradiation versus those without irradiation (100% vs. 50%; p = 0.010), and the hypoparathyroidism rate was significantly higher in the PLTE versus non-PLTE patients (100% vs. 50%; p = 0.026). The mean levothyroxine dosage was 1.60 μg/kg/day in the PLE patients post-irradiation.
Irradiation appears to be a risk factor for hypothyroidism after PLE with thyroid lobectomy, while PLTE might have some effect on hypoparathyroidism. Due to vocal function loss, PLE patients may experience symptoms from endocrine complications. Levothyroxine treatment soon after PLE for post-irradiation patients and patients requiring as-needed calcium or vitamin D supplementation based on biochemical hypocalcemia for PLE (especially PLTE), may be effective in preventing symptomatic endocrine complications.
无法保留喉功能的颈段食管癌(CEC)患者常接受放化疗,而残留或复发病变的患者则行咽-喉-食管切除术(PLE);然而,一些患者由于同步或异时性食管癌需要行全食管切除-咽喉切除术(PLTE)。我们回顾性评估了 CEC 患者术前放疗(或食管切除范围)与术后内分泌并发症(包括甲状腺功能减退症和甲状旁腺功能减退症)之间的关系。
2000 年至 2017 年间,678 例行食管切除术的食管癌患者中有 35 例(5.4%)为 CEC。我们还分析了 17 例接受 PLE 加甲状腺叶切除术的 CEC 患者,其中 11 例在 PLE 前行放疗,6 例未行放疗。7 例患者行 PLTE。
分别有 14 例和 12 例患者发生甲状腺功能减退症和甲状旁腺功能减退症。行放疗的患者甲状腺功能减退症发生率明显高于未行放疗的患者(100% vs. 50%;p=0.010),行 PLTE 的患者甲状旁腺功能减退症发生率明显高于非 PLTE 患者(100% vs. 50%;p=0.026)。行放疗的 PLE 患者术后左甲状腺素剂量平均为 1.60μg/kg/天。
放疗似乎是 PLE 加甲状腺叶切除术后发生甲状腺功能减退症的危险因素,而 PLTE 可能对甲状旁腺功能减退症有一定影响。由于丧失发声功能,PLE 患者可能会出现内分泌并发症的症状。PLE 后行放疗的患者应尽快开始左甲状腺素治疗,对于需要补钙或维生素 D 的患者(尤其是 PLTE)应根据生化低钙血症按需补充,这可能有助于预防有症状的内分泌并发症。